Our Story

UroMems was founded in 2011 and focuses on designing, developing, and commercializing active implantable medical devices.

As a global medical device company, UroMems has locations in Europe and the U.S., including headquarters, manufacturing facilities and teams in two of the world-renowned med-tech centers: Grenoble, France, and Minneapolis, Minnesota.

UroMems is highly innovative and focuses on clearly identified clinical unmet needs, not only for their prevalence but also for their negative impact on each patient’s quality of life.

The UroMems name stems from microelectromechanical systems or myoelectromechanical systems (MEMS), the technology that powers UroActive™ and one of the most revolutionary technologies with the potential to transform industrial and consumer products. MEMS combines silicon-based microelectronics and micromachining technology with applications in an extensive range of markets including medical, automotive, electronic, communication and defense.


Co-founded by practicing urologist and Sorbonne University professor Pierre Mozer, MD, PhD; biomedical engineer Hamid Lamraoui, PhD; and smart med device serial entrepreneur Stéphane Lavallée, PhD, UroMems is guided by a medical device industry dream team including:

  • 8 top leaders in management each with 15-25 years of experience
  • 10 board members including large VCs and C-suite executives
  • 4 renowned clinical advisors
  • More than 60 highly skilled engineers and experts in R&D, manufacturing, quality, regulatory, clinical, medical, European patent attorney and marketing

UroMems owns a robust intellectual property portfolio, including:

  • More than 150 patents/applications in force worldwide
  • More than 10 trademarks

UroMems has received prestigious global awards, including:

  • 2015 World Innovation Challenge Award
  • 2019 Prix Galien MedStartUp

Significant investments have been made in the development of UroMems’ first innovation, for a total amount of €46 million, including two financing rounds with Wellington Partners, Bpifrance, Supernova Invest, b-to-v Partners AG, Cita Investissement, Hil-Invent, Financière Arbevel and the founders.


Our mission

UroMems’ mission is to offer groundbreaking, smart implantable solutions that are:

  • Easy to use for patients
  • Easy to operate for healthcare professionals
  • Smarter, more dynamic, adaptive and less invasive than current surgical techniques

In a particularly demanding economic and regulatory context, the company’s focus is to improve current surgical treatments to help as many patients as possible, particularly by reducing associated side effects.

In order to deliver on this goal, UroMems innovates in a leading-edge technology environment and has established partnerships with internationally renowned experts, research laboratories, hospital, universities and industrial partners.

Led by the founders’ vision, UroMems adheres to the strictest ethics.